1. Scrip
  2. >>Business
  3. >>Manufacturing

Approval Delayed, But Janssen/Legend’s Cilta-Cel May Hit Market Just In Time

BMS/Bluebird’s Abecma Approved But Demand Exceeds Supply

 
• By Mandy Jackson

The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.

Close up of hourglass clock on a wooden floor
Time will tell if a three-month approval delay is meaningful for cilta-cel • Source: Alamy

Janssen Pharmaceutical Cos. and Legend Biotech Corp. will have to wait an extra three months for a US Food and Drug Administration approval decision on their chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel (cilta-cel) but given the manufacturing challenges facing first-to-market Abecma (idecabtagene vicleucel) there may be pent-up demand for another B-cell maturation antigen (BCMA)-targeting CAR-T product by the time cilta-cel reaches the market for multiple myeloma.

Johnson & Johnson subsidiary Janssen and Legend announced on 1 November that the FDA has moved the action date for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

 
• By Anju Ghangurde

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

More from Business